PSTV Plus Therapeutics Inc

Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer

Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer

AUSTIN, Texas, July 02, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that Melissa Moore, Ph.D., Vice President, Clinical Research and Development, will give a presentation at 11:30 a.m. EDT at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer on July 8, 2024 in Newry, Maine.

The presentation will report data from the ReSPECT-GBM and ReSPECT-LM clinical studies evaluating the Company’s lead radiotherapeutic, rhenium (186Re) obisbemeda, for the treatment of recurrent glioblastoma (GBM) and leptomeningeal metastases (LM).

Details of presentations:

TitleTargeted Radiolabeled Nanoliposomes for Rare CNS Cancers: An Update on the

ReSPECT Phase 1/2 Trials
  
DateJuly 8, 2024, 11:30 a.m. EDT
  
SessionClinical Trial Updates in Radionuclide Theranostics



About Plus Therapeutics

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. For more information, visit .

Investor Contact

Charles Y. Huang, MBA

Director of Capital Markets and Investor Relations

Office: (202)-209-5751 | Direct (301)-728-7222



EN
02/07/2024

Underlying

PSTVPlus Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Plus Therapeutics Inc

 PRESS RELEASE
Free
PSTV Plus Therapeuti...

Plus Therapeutics Announces New Category III CPT Code for Convection-E...

Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™ Unlocks market access and growth potential of REYOBIQ therapy in recurrent glioblastoma and pediatric brain cancer by enabling adoption and utilization tracking HOUSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced the American Medical Association’s (AMA) CPT® (Current Procedural Term...

February 25, 2026 1 EN
 PRESS RELEASE
Free
PSTV Plus Therapeuti...

Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Progra...

Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization Expands CNSide Clinical License in State of Pennsylvania HOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today provides a business update and highlights REYOBIQ clinical progress and CNSide US commercialization. “Our 2 key goals in 2026 are CNSide commercial scale-up and REYOBIQ pivotal trial...

January 22, 2026 1 EN
 PRESS RELEASE
Free
PSTV Plus Therapeuti...

Plus Therapeutics to Provide Business Update and Host Conference Call ...

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that the Company will provide a business update on Thursday, January 22, 2026 before the market open. Plus Therapeutics’ management team will then host a conference call and webcast at 9:00 a.m. ET to discuss and provide ad...

January 21, 2026 1 EN
 PRESS RELEASE
Free
PSTV Plus Therapeuti...

Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offe...

Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering HOUSTON, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces the pricing of its underwritten public offering of 39,473,684 units, with each unit consisting of one share of common stock and one warrant (the “Warrants”). Each unit is being sold to the public at a price of $0.38 per unit. The gross proceeds to the Company from...

January 14, 2026 1 EN
 PRESS RELEASE
Free
PSTV Plus Therapeuti...

Plus Therapeutics Announces Read Out of Type B Meeting with the FDA wi...

Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases On track to define optimal dosing interval and advance manufacturing scale up of REYOBIQ for pivotal trial readiness in late 2026 HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: ) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the completion of a Type B meeting with the U.S. Food and Drug Administration (FDA) o...

January 8, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch